Dyskinesias
Mostrando 1-12 de 45 artigos, teses e dissertações.
-
1. Complicações motoras e não motoras na levodopaterapia na doença de Parkinson / Motor and non-motor complications in levodopa therapy in Parkinson s
Study the motor and non-motor complications in a group of patients with Parkinson´s disease (PD) treated with levodopa (LD). Motor and non-motor complications were assessed in 61 patients (22 women and 39 men) with PD using LD. The Unified Parkinson s Disease Rating Scale (UPDRS), Hoehn &Yahr staging and Schwab &England ADL scale were used to assess the pat
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 28/02/2012
-
2. An examination of synaptic proteins following chronic haloperidol in a rat model of tardive dyskinesia
Tardive dyskinesia (TD) is a late-onset side effect mainly affecting the orofacial region of patients treated chronically with classic antipsychotic drugs such as haloperidol (HAL). The causes of TD remain unknown. We hypothesized that faulty synaptic re-organization might be related to TD-like syndromes and used the vacuous chewing movements (VCM) model in
Psychology & Neuroscience. Publicado em: 2010-12
-
3. Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats
7-Nitroindazole (7-NI) inhibits neuronal nitric oxide synthase in vivo and reduces l-DOPA-induced dyskinesias in a rat model of parkinsonism. The aim of the present study was to determine if the anti-dyskinetic effect of 7-NI was subject to tolerance after repeated treatment and if this drug could interfere with the priming effect of l-DOPA. Adult male Wista
Brazilian Journal of Medical and Biological Research. Publicado em: 2010-11
-
4. EFEITOS DOS NEUROLÉPTICOS ATÍPICOS ZIPRASIDONA E AMISULPRIDA EM MODELOS ANIMAIS DE DISCINESIA TARDIA.
Tardive dyskinesia - the main side effect of long-term treatment with typical neuroleptics - has been related to nigrostriatal dopaminergic supersensitivity. Treatment with atypical neuroleptics is associated with a decreased risk for development of tardive dyskinesia. The aim of the present study was to verify the effects of several doses the atypical neuro
Publicado em: 2009
-
5. Factores asociados con el desarrollo de complicaciones no motoras en la enfermedad de Parkinson
Parkinson's disease (PD) is a neurodegenerative disorder, predominantly characterized by the presence of motor symptoms. However, the non motor manifestations (NMM) are a frequent complaint in the PD patients. There is a lack of information about the risk factors associated with the NMM in these patients. The aim of this study is to evaluate the prevalence o
Arquivos de Neuro-Psiquiatria. Publicado em: 2008-03
-
6. Parkinsonism related disorders and use of levodopa: a study on motor fluctuations and oropharyngeal function / Complicações relacionadas a progressão da doença de Parkinson e ao uso de levodopa: um estudo sobre flutuações motoras e função orofaringea
Pacientes com doença de Parkinson (DP) desenvolvem freqüentemente flutuações motoras com perda de beneficio terapêutico. A levodopa permanece como agente dopaminérgico mais efetivo, entretanto, após alguns anos de tratamento observa-se geralmente flutuações motoras e discinesias. A ocorrência destas complicações é responsável por incapacidade e
Publicado em: 2003
-
7. Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics.
Anticonvulsants cause dyskinesias more commonly than has been appreciated. Diphenylhydantoin (DPH), carbamazepine, primidone, and phenobarbitone may cause asterixis. DPH, but not other anticonvulsants, may cause orofacial dyskinesias, limb chorea, and dystonia in intoxicated patients. These dyskinesias are similar to those caused by neuroleptic drugs and may
-
8. Attempted use of haloperidol in the treatment of L-dopa induced dyskinesias1
Haloperidol was used in 12 patients in an attempt to improve l-dopa induced dyskinesias. In eight patients any improvement in dyskinesias was associated with increased Parkinsonism. In four patients the dyskinesias initially improved without clinical deterioration. Within several weeks, however, the disability due to Parkinsonism increased in these four pati
-
9. Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease.
Chronic thalamic stimulation was performed in 10 Parkinsonian patients with disabling tremor and poor response to drug therapy. During the stereotactic procedure, an electrode was introduced in the ventralis intermediate nucleus of the thalamus. Test stimulation was performed during the intra-operative procedure and a few days after surgery using an external
-
10. The dopaminergic response in multiple system atrophy.
Fifteen of 23 pathologically confirmed cases of multiple system atrophy (MSA) showed some initial response to levodopa and eight of these remained at least partially responsive at the time of death. Eleven developed motor oscillations, and drug-induced dyskinesias, often involving the face and jaw, were also seen in 11 cases. Acute levodopa and apomorphine c
-
11. Analysis of l-dopa induced dyskinesias in 51 patients with Parkinsonism
An analysis of 51 patients with Parkinsonism who have developed L-dopa induced dyskinesias is presented. The cause has not been proven, although various hypotheses are discussed. One third of the total number of patients treated developed dyskinesia. These patients tend to respond better to L-dopa than the other group. There is a tendency for the older patie
-
12. Sodium valproate in the treatment of levodopa-induced dyskinesia.
The effect of sodium valproate 1200 mg daily on the disability of Parkinsonism and on levodopa-induced dyskinesia was assessed in a double-blind crossover trial with matched placebo in 12 patients with Parkinson's disease. No objective change in the severity of Parkinsonism or dyskinesias was noted. However, six out of nine patients who completed the trial n